RAS screening in colorectal cancer: a comprehensive analysis of the results from the UK NEQAS colorectal cancer external quality assurance schemes (2009

RAS screening in colorectal cancer: a comprehensive analysis of the results from the UK NEQAS colorectal cancer external quality assurance schemes (2009–2016)

Published:2017-06-26 Issue:6 Volume:471 Page:721-729
ISSN:0945-6317
Container-title:Virchows Archiv
language:en
Short-container-title:Virchows Arch

Author:

Richman Susan D.,Fairley Jennifer,Butler Rachel,Deans Zandra C.

Funder

UK NEQAS

Medical Research Council

Publisher

Springer Science and Business Media LLC

Subject

Cell Biology,Molecular Biology,General Medicine,Pathology and Forensic Medicine

Link

http://link.springer.com/article/10.1007/s00428-017-2162-7/fulltext.html

Reference23 articles.

1. A. Jung GB, M.Dietel, H. Gabbert, H.Kreipe, W. Schlake, A. Tannapfel, M. von Knebel Doberitz and T. Kirchner (2009) The German quality assurance system for the molecular-pathological detection of KRAS-mutations in colorecal cancer ASCO Annual meeting, pp 4018

2. Allegra CJ, Rumble RB, Schilsky RL (2016) Extended RAS gene mutation testing in metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy: American Society of Clinical Oncology provisional clinical opinion update 2015 summary. J Oncol Pract 12:180–181. doi: 10.1200/JOP.2015.007898

3. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, Patterson SD, Chang DD (2008) Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26:1626–1634. doi: 10.1200/JCO.2007.14.7116

4. Bellon E, Ligtenberg MJ, Tejpar S, Cox K, de Hertogh G, de Stricker K, Edsjo A, Gorgoulis V, Hofler G, Jung A, Kotsinas A, Laurent-Puig P, Lopez-Rios F, Hansen TP, Rouleau E, Vandenberghe P, van Krieken JJ, Dequeker E (2011) External quality assessment for KRAS testing is needed: setup of a European program and report of the first joined regional quality assessment rounds. Oncologist 16:467–478. doi: 10.1634/theoncologist.2010-0429

5. Bokemeyer C, Bondarenko I, Hartmann JT, de Braud F, Schuch G, Zubel A, Celik I, Schlichting M, Koralewski P (2011) Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol 22:1535–1546. doi: 10.1093/annonc/mdq632

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The utility of c‐Met as a diagnostic tissue biomarker in primary colorectal cancer;International Journal of Experimental Pathology;2021-05-05

2. Actualización de la recomendación para la determinación de biomarcadores en el carcinoma colorrectal. Consenso Nacional de la Sociedad Española de Oncología Médica y de la Sociedad Española de Anatomía Patológica;Revista Española de Patología;2021-01

3. Causes behind error rates for predictive biomarker testing: the utility of sending post-EQA surveys;Virchows Archiv;2020-11-23

4. Managing Deviating EQA Results: A Survey to Assess the Corrective and Preventive Actions of Medical Laboratories Testing for Oncological Biomarkers;Diagnostics;2020-10-18

5. Biomarker testing in oncology – Requirements for organizing external quality assessment programs to improve the performance of laboratory testing: revision of an expert opinion paper on behalf of IQNPath ABSL;Virchows Archiv;2020-10-13